查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827877

生技药品市场按产品类型、技术、给药途径、治疗领域、最终用户和分销管道划分 - 全球预测 2025-2032

Biologics Market by Product Type, Technology, Route Of Administration, Therapeutic Area, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年生技药品市场规模将成长至 7,191.7 亿美元，复合年增长率为 6.62%。

主要市场统计数据
基准年2024年 4305.9亿美元
预计2025年 4594.5亿美元
预测年份：2032年 7191.7亿美元
复合年增长率（%） 6.62%

简洁、综合地概述了当前生技药品的动态、衔接科学创新、商业性压力点以及领导者的营运重点

生技药品处于尖端科学与复杂商业动态的交会点，正在重新定义多个治疗领域的治疗模式。本执行摘要整合了当前的结构性变化、监管和商业压力、细分市场主导的机会以及区域考量，旨在为负责掌握近期策略格局的高层领导者提供清晰的叙述。本摘要汇集了平台创新、生产和分销载体以及相关人员期望等方面的证据，旨在帮助高阶主管明确投资、伙伴关係和营运协调的优先事项。

本书重点阐述了产品创新与大规模提供疗法所需的生态系统之间的相互作用，涵盖从上游研发技术到下游分销管道的各个环节。本书也强调了政策、供应链韧性和付款人方式的变化如何重塑商业性路径。本书的引言透过阐述关键讯号和实际意义，为后续章节奠定了基础，这些章节旨在为参与生技药品开发、生产和交付的组织提供高层策略和可操作的倡议。

科学、监管和营运的演变如何重塑生技药品的开发、製造灵活性和商业化策略

在日趋成熟的技术、新的法律规范以及相关人员不断变化的期望的推动下，生技药品领域正在经历重大变革。基因编辑技术的进步和平台的改进，正在将先前的实验性方法推向更具临床可行性的领域，从而加速了人们对罕见和复杂疾病的标靶治疗方法的兴趣。同时，製造模式正在转向模组化、灵活的生产能力，以缩短前置作业时间并提高对临床需求的应对力，从而改变了整个价值链的资本配置和伙伴关係关係。

不断变化的政策和支付方正在为基于结果的合约和证据生成创造新的奖励，这正在影响研究设计、核准后数据承诺和商业化策略。数位化工具和数据互通性正在增强患者参与度和分散式临床试验模式，从而实现更有效率的招募和更丰富的纵向证据。同时，供应链优先排序（包括原料采购、低温运输物流和生产冗余）已成为营运的当务之急。总的来说，这些转变既创造了差异化的机会，也带来了重塑传统经营模式的压力，促使组织采用整合的跨职能方法，以协调研发、製造、法规事务和商业规划。

评估 2025 年关税如何改变生技药品相关人员的供应链采购、区域产能决策与筹资策略

2025年实施的最新关税为生技药品相关人员带来了额外的复杂性，影响了跨区域采购、生产布局以及整个供应链的成本结构。针对特定投入、设备或成品生物製药，促使许多公司重新评估筹资策略，深化与本地供应商的关係，并加速双重采购以降低风险。这些调整需要更复杂的采购分析、重新协商供应商合同，并与物流合作伙伴更紧密地协调，以保持关键试剂和组件的连续性。

为了应对关税带来的不确定性，製造商重新审视了其产能分配决策和资本投资，并更加重视能够服务重点市场并最大程度减少跨境摩擦的区域生产基地。监管机构和行业协会加强了对话，以明确分类规则并加快温度敏感货物的清关速度，从而减轻了部分营运负担。同时，付款人和医疗保健提供者正密切关注潜在的下游成本影响，并引发了关于将关税影响纳入考虑的报销框架和总医疗成本模型的讨论。最终，2025年关税的累积影响已将地缘政治考量提升至生技药品公司策略规划的核心要素，影响从研发地点选择到商业化排序和伙伴关係结构的决策。

透过整合细分洞察推动策略协调，将产品模式、实行技术、交付途径、治疗重点、护理环境和分销方法连结起来

细分领域的分析揭示了产品类型、技术、给药途径、治疗领域、最终用户和分销管道之间的独特动态，每种动态都需要不同的策略应对措施。按产品类型划分，血液因子产品、单株抗体、重组蛋白和疫苗等仍是基础生物製药类别，拥有成熟的生产和监管途径；而细胞和基因疗法则正从专业中心向更广泛的商业网络发展。具体而言，细胞疗法分为CAR-T疗法和干细胞疗法，每种疗法都有其独特的开发途径、生产限制和医疗服务模式，这些都会影响临床部署策略。

同时，基因编辑技术（例如 CRISPR、TALEN 和锌指核酸酶）为精准医疗提供了强大的选择，但也引发了有关监管协调和长期监测的新考虑。不同的给药途径——肌肉注射、静脉注射和皮下注射——决定了患者的获取策略、低温运输需求和临床经济学。治疗领域——自体免疫疾病、心血管疾病、感染疾病、代谢性疾病、神经系统疾病和肿瘤学——指导临床开发的优先顺序和证据生成路径。最终使用者——诊所、居家医疗服务、医院和研究机构——决定了分销、培训和支援模式。最后，分销管道的选择——医院药房、线上通路或零售药房——会影响履约方式、病患依从性倡议和商业伙伴关係设计。结合这些细分视角，可以提供一个实用的框架，使研发投资、製造设计和上市模式与每种治疗方法和卫星群的固有需求保持一致。

在多样化的全球医疗保健生态系统中协调製造、监管参与和商业化的区域要务和差异化策略

区域动态创造了独特的机会和营运需求，需要采取差异化的市场准入、监管参与和生产力计画方法。在美洲，成熟的临床生态系统和先进的製造群持续吸引对复杂模式和后期开发的投资，而政策对话和付款人结构则影响商业化顺序和证据要求。在该地区运营的公司通常优先考虑可扩展的生产和强大的上市后证据策略，以适应成熟的供应商网路和报销模式。

在欧洲、中东和非洲，相关人员面临部分地区成熟的法律规范，而其他地区则面临产能受限的市场。监管协调工作和共用采购机制可以支援更广泛的准入，但基础设施和定价政策的差异使得灵活的商业性方式成为必要。亚太地区的条件高度多样化，一些市场提供快速进入途径并不断提升临床试验能力，而另一些市场则专注于建立製造和监管能力。在许多亚太市场，优惠的政策奖励和不断增长的医疗保健需求正在推动企业加快技术转移、建立本地伙伴关係关係和区域规模生产，以应对国内和出口机会。在所有地区，将製造地、监管参与和商业化模式与当地结构性现实相结合仍然是成功的关键。

领先的生技药品公司如何结合伙伴关係、模组化製造和跨职能管治，以确保竞争性执行和价值交付

主要企业的生技药品公司正透过策略伙伴关係关係、有针对性的产能投资和专注的产品组合开发等方式增强其竞争地位，并专注于平台扩充性和法规合规性。那些将内部能力与外部合作伙伴（例如合约生产企业 (CM​​O)、学术中心和利基技术提供者）进行策略性整合的公司，能够更好地管理研发的复杂性，并加速从实验室创新到临床应用的转化进程。对模组化製造和用于製程控制的高级分析的投资，使批次品质更加可预测，技术转移速度更快，并已成为其独特的营运能力。

同时，成功的公司正在积极与监管机构和付款方合作，共同设计能够展现现实世界价值的证据生成策略，并在适当情况下协商获得有条件核准或管理准入协议的途径。商业成熟度也在不断提高，领先的公司正在建立全面的患者支持生态系统和创新的分销结构，以提升医院、诊所、居家照护机构、零售店和线上管道的覆盖率。在技​​术创新日新月异、相关利益者期望不断变化等背景下，人才培养和整合研发、製造、商业性团队的跨职能管治结构正成为推动持续执行的关键相关人员。

为领导者提供实际的优先行动，以加强生技药品供应链、监管参与、製造敏捷性和商业性准备

产业领导者应优先考虑一系列具体行动，以增强韧性、加速商业化进程，并在管理风险的同时获得临床价值。首先，将策略供应链审查纳入企业规划週期，以评估采购集中度，并明确区域产能扩张和双重采购的标准。其次，在临床生命週期的早期，将产品开发蓝图与监管机构和付款方的证据要求一致，以减少下游摩擦，并实现更灵活的商业化路径。第三，投资模组化製造平台和数位化流程控制，以缩短技术转移时间，并支持优先治疗模式的快速扩展。

同时，建立严谨的伙伴关係策略，将内部优势与先进技术、契约製造和专业临床网路等外部能力结合，并正式建立包含共用资料标准和管治的合作。透过设计针对给药途径和最终用户环境的分销和患者支援计划来强化商业模式，确保为医院、诊所、居家医疗和药房管道提供适当的临床培训和供应连续性措施。最后，与监管机构保持适应性接触，以预测政策变化，并儘早参与有关分类、核准途径和上市后义务的对话。实施这些优先步骤将使公司能够更灵活地应对地缘政治和技术变革，同时为持续的临床和商业性影响铺平道路。

我们的多方法研究途径结合了专家访谈、技术文献分析和商业案例审查，以提供基于证据的策略指导

本报告采用多种方法，整合了一手和二手研究，包括质性专家访谈、技术文献综述和营运案例分析。报告采访了开发、製造、监管事务和商业策略领域的专家，以获得关于平台采用、生产力计画和相关人员的第一手观点。报告也查阅了二手技术文献和监管指导文件，以检验相关机制和合奖励考量。该报告对近期技术转移和供应链重组的营运案例进行了分析，提供了实施挑战和缓解措施的实例。

数据整合强调了数据来源的可重复性和可追溯性，并记录了分析步骤，以支持对主题观察和含义的解释。调查方法结合了基于情境的敏感性检验，以测试策略建议在不同政策和营运环境下的适应性。自始至终，我们致力于将实证洞见转化为可供决策者操作的指导，同时公开证据的局限性，并清晰地指出哪些进一步的初步研究将有益于特定组织的决策。

综合策略意义，强调生技药品创新需要韧性、跨职能编配与能力投资

生技药品领域正处于曲折点，科学突破与复杂的商业性现实交织在一起，既带来了高期望，也带来了日益增长的营运需求。积极拥抱供应链韧性、监管和付款人参与、生产敏捷性以及细分主导的商业化的组织，最有能力将科学进步转化为患者效益和永续的业务成果。基因编辑和模组化製造等技术进步拓展了可行的治疗策略。

未来的成功将取决于各组织协调跨职能能力、建立务实伙伴关係关係以及采用能够反映当地监管和医疗服务环境的循证商业化模式的能力。相关人员应将当前环境视为重塑传统营运模式的机会，并投资于支持快速可靠地交付复杂生技药品的能力。这样做将有助于缓解短期中断，并抓住下一波生技药品创新浪潮带来的长期临床和商业性利益。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 主要医药市场迅速采用生物相似药互换性指南，推动价格竞争
  • 引入一次性生物反应器技术，缩短开发时间并降低交叉污染风险
  • 整合单株抗体生产的连续製造工艺，以提高可扩展性并降低成本
  • 利用针对罕见遗传疾病的新型病毒载体平台扩展基因治疗产品线
  • 应用人工智慧驱动的细胞株开发来优化克隆选择并提高生物过程产量
  • 生物製药公司与CDMO之间的策略合作伙伴关係拓展了高效生技药品和基因疗法的能力
  • 主要市场的监管协调将加速生物相似药和下一代生物疗法的全球核准
  • 增加对蛋白质疗法新型递送平台的投资，以提高患者依从性和药物动力学

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章生技药品市场（依产品类型）

  • 血液因子产品
  • 细胞疗法
    • CAR-T疗法
    • 干细胞疗法
  • 基因治疗
  • 单株抗体
  • 重组蛋白
  • 疫苗

第九章生技药品市场（依技术）

  • 细胞培养技术
  • 基因编辑技术
    • CRISPR
    • TALENs
    • 锌指核酸酶
  • 融合瘤技术
  • 重组DNA技术

第十章生技药品市场（依给药途径）

  • 肌肉注射
  • 静脉
  • 皮下

第 11 章生技药品市场（依治疗领域）

  • 自体免疫
  • 心血管疾病
  • 感染疾病
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤学

第 12 章生技药品市场（依最终使用者）

  • 诊所
  • 家庭医疗保健
  • 医院
  • 研究机构

第十三章生技药品市场（依通路）

  • 医院药房
  • 线上管道
  • 零售药局

第十四章生技药品市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章生技药品市场：依类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国生技药品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Roche Holding AG
    • AbbVie Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi SA
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
Product Code: MRR-4302AC72200D

The Biologics Market is projected to grow by USD 719.17 billion at a CAGR of 6.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 430.59 billion
Estimated Year [2025] USD 459.45 billion
Forecast Year [2032] USD 719.17 billion
CAGR (%) 6.62%

A concise, integrated overview of current biologics dynamics bridging scientific innovation, commercial pressure points, and operational priorities for leaders

Biologics sit at the intersection of advanced science and complex commercial dynamics, redefining treatment paradigms across multiple therapeutic areas. This executive summary synthesizes current structural shifts, regulatory and trade pressures, segmentation-driven opportunities, and regional considerations to provide a coherent narrative for senior leaders tasked with navigating the near-term strategic landscape. It brings together evidence on platform innovations, manufacturing and distribution vectors, and stakeholder expectations so that executives can prioritize investments, partnerships, and operational adjustments with clarity.

The narrative emphasizes the interplay between product innovation and the ecosystems required to deliver therapies at scale, from upstream R&D technologies through to downstream distribution channels. It highlights how changes in policy, supply chain resilience, and payer approaches are reshaping commercial pathways. By framing the key signals and practical implications, the introduction sets a foundation for reading subsequent sections as a connected set of insights intended to inform both high-level strategy and actionable initiatives within organizations active across biologics development, production, and delivery.

How convergent scientific, regulatory, and operational evolutions are reshaping biologics development, manufacturing flexibility, and commercialization strategies

The biologics landscape is undergoing transformative shifts driven by converging technological maturation, new regulatory frameworks, and evolving stakeholder expectations. Gene editing advancements and platform refinement have pushed previously experimental approaches into more clinically viable territories, accelerating interest in therapies that target rare and complex conditions. At the same time, manufacturing paradigms are shifting toward modular, flexible capacity to reduce lead times and increase responsiveness to clinical demand, altering capital allocation and partnership calculus across the value chain.

Policy and payer evolution are creating fresh incentives for outcome-based contracting and evidence generation, which in turn influence trial design, post-approval data commitments, and commercialization strategies. Digital tools and data interoperability are enhancing patient engagement and decentralized trial models, enabling more efficient recruitment and richer longitudinal evidence. Meanwhile, supply chain prioritization-spanning raw material sourcing, cold-chain logistics, and production redundancy-has become an operational imperative. These shifts collectively create both opportunities for differentiation and pressure to reconfigure traditional business models, encouraging organizations to adopt integrated cross-functional approaches that align R&D, manufacturing, regulatory affairs, and commercial planning.

Assessing how 2025 tariff measures have altered supply chain sourcing, regional capacity decisions, and procurement strategies for biologics stakeholders

Recent tariff actions instituted in 2025 introduced an additional layer of complexity for biologics stakeholders, affecting multi-jurisdictional procurement, manufacturing footprints, and cost structures across supply chains. Tariff measures that target specific inputs, equipment, or finished biologic products have prompted many organizations to reassess sourcing strategies, deepen local supplier relationships, and accelerate dual-sourcing initiatives to mitigate exposure. These adjustments have required more sophisticated procurement analytics, renegotiation of supplier contracts, and closer coordination with logistics partners to preserve continuity of critical reagent and component flows.

In response to tariff-driven uncertainties, manufacturers have also revisited capacity allocation decisions and capital investments, placing greater emphasis on regional production nodes that can serve priority markets with minimal cross-border friction. Regulatory authorities and industry groups have increasingly engaged in dialogue to clarify classification rules and to expedite customs procedures for temperature-sensitive shipments, which has eased some operational burdens. Simultaneously, payers and providers are attentive to potential downstream cost implications, prompting discussions about reimbursement frameworks and total-cost-of-care models that account for tariff effects. Ultimately, the cumulative impact of the 2025 tariff measures has elevated geopolitical considerations as a core element of strategic planning for biologics companies, influencing decisions from R&D site selection to commercialization sequencing and partnership structuring.

Integrated segmentation insights linking product modalities, enabling technologies, delivery pathways, therapeutic focuses, care settings, and distribution approaches for strategic alignment

Segment-level analysis reveals differentiated dynamics across product types, technologies, routes of administration, therapeutic areas, end users, and distribution channels, each demanding distinct strategic responses. Within product typologies, modalities such as blood factor products, monoclonal antibodies, recombinant proteins, and vaccines continue to represent foundational biologic classes with established manufacturing and regulatory pathways, while cell therapies and gene therapies are advancing from specialized centers toward broader commercial networks. Cell therapies specifically bifurcate into CAR-T therapies and stem cell therapies, each with unique development pathways, manufacturing constraints, and care-delivery models that affect clinical rollout strategies.

On the technology axis, the adoption and integration of cell culture platforms, hybridoma methods, and recombinant DNA approaches remain critical to optimizing yield and quality, whereas gene editing technology-comprising CRISPR, TALENs, and zinc finger nucleases-introduces powerful options for precision modalities but also raises new considerations around regulatory harmonization and long-term surveillance. Route-of-administration distinctions between intramuscular, intravenous, and subcutaneous delivery shape patient access strategies, cold-chain requirements, and site-of-care economics. Therapeutic area focus across autoimmune, cardiovascular diseases, infectious diseases, metabolic disorders, neurological disorders, and oncology directs clinical development prioritization and evidence generation pathways, while end users such as clinics, home healthcare services, hospitals, and research institutes determine distribution, training, and support models. Finally, distribution channel selection among hospital pharmacies, online channels, and retail pharmacies impacts fulfillment approaches, patient adherence initiatives, and the design of commercial partnerships. Taken together, these segmentation lenses provide a practical framework for aligning R&D investments, manufacturing design, and go-to-market models with the intrinsic needs of each therapeutic and delivery constellation.

Regional imperatives and differentiated strategies for aligning manufacturing, regulatory engagement, and commercialization across diverse global healthcare ecosystems

Regional dynamics are creating distinct opportunity contours and operational imperatives that require differentiated approaches to market entry, regulatory engagement, and capacity planning. In the Americas, established clinical ecosystems and advanced manufacturing clusters continue to attract investment in complex modalities and late-stage development, while policy dialogues and payer structures influence commercialization sequencing and evidence demands. Companies operating in this region frequently prioritize scalable manufacturing and robust post-market evidence strategies to align with sophisticated provider networks and reimbursement models.

Across Europe, the Middle East & Africa, stakeholders face a mix of mature regulatory frameworks in parts of Europe and capacity-constrained markets elsewhere, which encourages strategies that combine regional manufacturing hubs with tailored distribution partnerships. Regulatory harmonization efforts and shared procurement mechanisms can support wider access, but variations in infrastructure and pricing policies necessitate flexible commercial approaches. The Asia-Pacific region presents a highly heterogeneous set of conditions, with some markets offering rapid adoption pathways and growing clinical trial capacity while others focus on building manufacturing and regulatory capabilities. In many Asia-Pacific markets, favorable policy incentives and expanding healthcare demand are leading firms to accelerate technology transfer, local partnership formation, and regionally scaled production to serve both domestic and export opportunities. Across all regions, aligning manufacturing footprint, regulatory engagement, and commercialization models to local structural realities remains essential for success.

How leading biologics organizations are combining partnerships, modular manufacturing, and cross-functional governance to secure competitive execution and value delivery

Leading companies in the biologics space are consolidating their competitive positions through a blend of strategic partnerships, targeted capacity investments, and focused portfolio development that emphasizes platform scalability and regulatory readiness. Firms that strategically align their internal capabilities with external collaborators-such as CMOs, academic centers, and niche technology providers-are better positioned to manage development complexity and to accelerate translational pathways from laboratory innovations to clinical applications. Investment in modular manufacturing and advanced analytics for process control has become a distinguishing operational capability, enabling more predictable batch quality and faster tech transfer.

In parallel, successful organizations are proactively engaging regulators and payers to co-design evidence-generation strategies that demonstrate real-world value and to negotiate pathways for conditional approvals or managed-entry agreements where appropriate. Commercial sophistication is also rising, with leading players building comprehensive patient support ecosystems and innovative distribution arrangements to enhance uptake across hospitals, clinics, home care settings, and retail or online channels. Talent development and cross-functional governance structures that integrate R&D, manufacturing, regulatory affairs, and commercial teams are emerging as critical enablers for sustained execution in a landscape characterized by rapid technological change and evolving stakeholder expectations.

Practical and prioritized actions for leaders to strengthen supply chains, regulatory alignment, manufacturing agility, and commercial readiness in biologics

Industry leaders should prioritize a sequence of concrete actions designed to strengthen resilience, accelerate commercialization, and capture clinical value while managing risk. First, integrate strategic supply chain reviews into corporate planning cycles to assess sourcing concentration and to define criteria for regional capacity expansion and dual sourcing. Second, align product development roadmaps with regulatory and payer evidence requirements early in the clinical lifecycle to reduce downstream friction and to enable more flexible commercialization pathways. Third, invest in modular manufacturing platforms and digital process controls that reduce tech transfer timelines and support rapid scale-up for high-priority modalities.

In parallel, cultivate a disciplined partnership strategy that pairs internal strengths with external capabilities in advanced technologies, contract manufacturing, or specialized clinical networks, and formalize collaboration frameworks that include shared data standards and governance. Strengthen commercial models by designing distribution and patient-support programs tailored to route of administration and end-user settings, ensuring that hospital, clinic, home care, and pharmacy channels are each supported with appropriate clinical training and supply continuity measures. Finally, maintain an adaptive regulatory engagement posture to anticipate policy shifts and to participate in early dialogues on classification, approval pathways, and post-market obligations. Executing these prioritized steps will position organizations to respond more nimbly to geopolitical and technological disruptions while unlocking pathways to sustained clinical and commercial impact.

A multi-method research approach combining expert interviews, technical literature analysis, and operational case reviews to produce evidence-driven strategic guidance

This report synthesizes primary and secondary research inputs, structured around a multi-method approach that triangulates qualitative expert interviews, technical literature review, and operational case analysis to ensure robust, evidence-driven conclusions. Interviews were conducted with subject-matter experts across development, manufacturing, regulatory affairs, and commercial strategy to capture first-hand perspectives on platform adoption, capacity planning, and stakeholder incentives. Secondary technical literature and regulatory guidance documents were examined to validate mechanistic and compliance considerations, while operational case analyses of recent technology transfers and supply chain reconfigurations provided practical illustrations of execution challenges and mitigations.

Data synthesis emphasized reproducibility and traceability of sources, with analytic steps documented to support interpretation of thematic findings and implications. The methodology incorporated scenario-based sensitivity checks to test the resilience of strategic recommendations under differing policy and operational conditions. Throughout, the emphasis remained on translating empirical insights into actionable guidance for decision-makers, with transparency about evidence limitations and clear signposts for where further primary investigation would be valuable for organization-specific decisions.

Synthesis of strategic implications highlighting the need for resilience, cross-functional orchestration, and capability investments to capture biologics innovation

The biologics field is at an inflection point where scientific breakthroughs and complex commercial realities intersect, creating both significant promise and heightened operational demands. Organizations that proactively address supply chain resilience, regulatory and payer engagement, manufacturing agility, and segmentation-driven commercialization will be best positioned to translate scientific advances into patient impact and sustainable business outcomes. The cumulative effects of recent trade and policy shifts underscore the necessity of integrating geopolitical risk into core strategic decisions, while technology advances such as gene editing and modular manufacturing expand the palette of viable therapeutic strategies.

Moving forward, success will hinge on an organization's ability to orchestrate cross-functional capabilities, to form pragmatic partnerships, and to adopt evidence-centered commercialization models that reflect local regulatory and delivery contexts. Stakeholders should view the current environment as an opportunity to reconfigure traditional operating models and to invest in capabilities that support faster, more reliable delivery of complex biologics. By doing so, they can both mitigate short-term disruptions and position themselves to capture the long-term clinical and commercial benefits arising from the next wave of biologics innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of biosimilar interchangeability guidelines within major pharmaceutical markets driving competitive pricing
  • 5.2. Implementation of single-use bioreactor technologies to accelerate development timelines and reduce cross-contamination risks
  • 5.3. Integration of continuous manufacturing processes in monoclonal antibody production to enhance scalability and reduce costs
  • 5.4. Expansion of gene therapy biologics pipelines with novel viral vector platforms targeting rare genetic disorders
  • 5.5. Application of AI-driven cell line development to optimize clone selection and improve bioprocess yields
  • 5.6. Strategic partnerships between biopharma companies and CDMOs to expand capacity for high-potency biologics and gene therapies
  • 5.7. Regulatory alignment across major markets facilitating global approvals of biosimilar and next-generation biologic therapies
  • 5.8. Growing investment in novel delivery platforms for protein therapeutics to improve patient adherence and pharmacokinetics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Market, by Product Type

  • 8.1. Blood Factor Products
  • 8.2. Cell Therapies
    • 8.2.1. CAR-T Therapies
    • 8.2.2. Stem Cell Therapy
  • 8.3. Gene Therapies
  • 8.4. Monoclonal Antibodies
  • 8.5. Recombinant Proteins
  • 8.6. Vaccines

9. Biologics Market, by Technology

  • 9.1. Cell Culture Technology
  • 9.2. Gene Editing Technology
    • 9.2.1. CRISPR
    • 9.2.2. TALENs
    • 9.2.3. Zinc Finger Nucleases
  • 9.3. Hybridoma Technology
  • 9.4. Recombinant DNA Technology

10. Biologics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Biologics Market, by Therapeutic Area

  • 11.1. Autoimmune
  • 11.2. Cardiovascular Diseases
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Oncology

12. Biologics Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Biologics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Channel
  • 13.3. Retail Pharmacy

14. Biologics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biologics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biologics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Holding AG
    • 17.3.2. AbbVie Inc.
    • 17.3.3. Pfizer Inc.
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Novartis AG
    • 17.3.6. Merck & Co., Inc.
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Amgen Inc.
    • 17.3.9. Bristol-Myers Squibb Company
    • 17.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. GLOBAL